Arek Z. Dudek, MD, PhD
Former Investigator, Metro-Minnesota Community Oncology Research Consortium and Physician Hematology/Oncology, Oncology

Affiliations/other offices held: University of Minnesota, University of Illinois at Chicago

Joined the Institute: 2016

Education and training: MD, Medical University of Warsaw, Poland; internal medicine residency, Pinnacle Health Hospitals, Harrisburg, PA; fellowship in hematology and oncology, University of Minnesota.

Overview/research interests: Dr. Dudek has been published more than 100 times in peer-reviewed medical journals for his work in lung cancer, melanoma and kidney cancer. In addition, he has written several editorials and book chapters on topics such as tumor biology and targeted cancer therapies. He serves as a research and clinical mentor to graduate students, junior faculty and clinicians.

Dr. Dudek discovered his calling to become a medical oncologist very early in medical school. He found cancer to be one of the most challenging human diseases, requiring the physician to have broad knowledge of all other medical disciplines and an understanding of cellular and molecular biology. The need for development of better therapies for cancer has led Dr. Dudek to look for novel cancer therapeutics and provide them to his patients who participate in cancer clinical trials in the early-phase clinical trials program at Regions Hospital.

Research activities and funding:

Phase Ib and Phase II Studies of anti-PD-1 Antibody MK-3475 in Combination with Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium BTCRC-GU14-003.

Source: Investigator Initiated Trial, supported by Merck.

Role: Principal Investigator          06/30/2017-06/29/2020

Phase II Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma: HCRN LUN15-299

Source: Investigator Initiated Trial, supported by Eli Lilly and Bristol-Myers Squibb.

Role: Study Chair  10/30/2018-06/29/2021

The primary objective is to evaluate activity of nivolumab immunotherapy in combination with antiangiogenic therapy in patients with unresectable malignant mesothelioma progressing after first line therapy.

A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination with Axitinib in Patients with Advanced Renal Cell Carcinoma

Source: X4 Pharmaceuticals, Inc.

Role: Site Principal Investigator  06/30/2017-06/29/2020

The primary objective is to evaluate the safety and tolerability of escalating dose levels of X4P-001, both in combination with axitinib and as single agent, in patients with advanced clear cell Renal Cell Carcinoma (ccRCC).

Anti-programmed Death – Ligand 1 Antibody, MEDI4736, in Combination with Chemotherapy for the First Line Treatment of Unresectable Mesothelioma

Source: AstraZeneca Pharmaceuticals, LP

Role: Site Principal Investigator  05/01/2017-05/01/2027

This is a clinical trial for patients with mesothelioma. Patients with pleural mesothelioma that cannot be surgically removed will receive durvalumab, in combination with standard chemotherapy as first-line treatment.

A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Source: Alliance Foundation Trials, LLC (AFT)

Role: Site Principal Investigator  03/04/01/2017-04/01/2027

This randomized trial provides dentists with simulated patients posing evidence-based challenges of effective treatment and build in treatment-specific decision support. We will assign HealthPartners dentists into a usual-care and simulation group and measure their treatment-planning patterns after the simulation group is exposed to evidence-based simulations and feedback support. We expect to find that the dentists exposed to the simulation encounters will exhibit practice patterns more congruent with successful patterns practiced in the simulation. While conducting this project, we will also plan the distribution of the simulation tool to the broader dental community.

An Open-label, Randomized, Controlled, Multicenter, Phase II Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax Pre-Nephrectomy Followed by Sunitinib Post-Nephrectomy, Compared to Sunitinib Post-Nephrectomy in Metastatic Renal Cell Carcinoma Patients

Source: Immunicum AB

Role: Site Principal Investigator  12/21/2016-06/01/2019

The company sponsoring this study, Immunicum AB, has developed an investigational vaccine called Intuvax that is injected directly into the kidney tumor. This vaccine consists of a type of white blood cells from healthy blood donors that have been pre-activated. It is hoped that by injecting these cells into a kidney tumor, a natural strong tumor and patient specific immune system response will start in order to fight the specific renal cancer cells throughout the kidney. This response may slow the progression of the renal cancer.

A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors

Source: Array BioPharma, Inc.

Role: Site Principal Investigator  09/01/2016-08/31/2018

The purpose of this study is to see how safe ARRY-382 (the study drug) is when given at different doses in combination with pembrolizumab (a drug for treatment of certain types of cancer) and to find the highest dose that can be given without causing unacceptable side effects.

Completed Research Support (within the last 3 years)

Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination with Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors

Source: Millennium

Role: Site Principal Investigator  05/01/2013-05/31/2016

Publications While At HealthPartners
selected publications
Journal Article
  • Phase 2 trial of nivolumab and ramucirumab for relapsed mesothelioma: HCRN-LUN15-299
    JTO Clin Res Rep. 2023
  • Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas
    Neurooncol Adv. 2023
  • Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies
    British Journal of Cancer. 2023
  • The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma
    Melanoma Research. 2023
  • ARRY-382 in combination with pembrolizumab in patients with advanced solid tumors: results from a phase 1b/2 study
    Clinical Cancer Research. 2022
  • MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
    Thoracic cancer. 2022
  • Markers of endothelial glycocalyx dysfunction in Clarkson disease
    Journal of Translational Medicine. 2022
  • A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction
    Supportive Care in Cancer. 2021
  • Alliance Foundation Trial 09: a randomized, multicenter, phase 2 trial evaluating two sequences of pembrolizumab and standard platinum-based chemotherapy in patients with metastatic NSCLC
    JTO Clin Res Rep. 2021
  • Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
    Nature Medicine. 2021
  • Immunoglobulin restores immune responses to BTH1677 in patients with low levels of antibodies to beta-glucan
    Anticancer Research. 2020
  • Impact of pain, opioids, and the mu-opioid receptor on progression and survival in patients with newly diagnosed stage IV pancreatic cancer
    American Journal of Clinical Oncology. 2020
  • Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy
    Breast Cancer Research and Treatment. 2020
  • Phase 1b study of IGF-methotrexate conjugate in the treatment of high-grade myelodysplastic syndromes
    Anticancer Research. 2020
  • Phase Ib/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003
    Journal of Clinical Oncology. 2020
  • Randomized study of maintenance pemetrexed versus observation for treatment of malignant pleural mesothelioma: CALGB 30901
    Clinical Lung Cancer. 2020
  • Two malignancies with differential responses to immune checkpoint inhibitors: a case report
    Anticancer Research. 2020
  • Phase I study of IGF-methotrexate conjugate in the treatment of advanced tumors expressing IGF-1R
    American Journal of Clinical Oncology. 2019
  • Phase I study of aurora A kinase inhibitor alisertib (MLN8237) in combination with selective VEGFR inhibitor pazopanib for therapy of advanced solid tumors
    American Journal of Clinical Oncology. 2019
  • Sphingosine-1-phosphate receptor 1 activity promotes tumor growth by amplifying VEGF-VEGFR2 angiogenic signaling
  • Adrenomedullin surges are linked to acute episodes of the systemic capillary leak syndrome (Clarkson disease)
    Journal of Leukocyte Biology. 2018
  • Efficacy and safety of sorafenib in a racially diverse patient population with advanced hepatocellular carcinoma
    Anticancer Research. 2018
  • Decline in arylsulfatase B leads to increased invasiveness of melanoma cells
  • Phase I study of pazopanib and ixabepilone in patients with solid tumors
    American Journal of Clinical Oncology. 2016
  • Prognostic value of serum proteomic test and comorbidity index in diversified population with lung cancer
    Anticancer Research. 2016
  • Phase II study of biweekly carboplatin, gemcitabine, and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC
    American Journal of Clinical Oncology. 2014
  • A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates
    American Journal of Clinical Oncology. 2012
  • Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients
    Journal of Oral and Maxillofacial Surgery. 2009
  • Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer
    Journal of Thoracic Oncology. 2008
  • Contact
    full name
  • Arek Z. Dudek, MD, PhD
  • Quick Info
    More Info